As for the GLP-1 albumin fusions, exposure to CPA resulted in removal of L585 and reduced FcRn binding of the WT albumin fusions, but not for the QMP-engineered counterparts (Supplementary Fig
One recently reported study comes from a sexual medicine clinic that routinely prescribes bremelanotide off-label to men
PCCA members with clinical services access may contact our Clinical Services team for help with sublingual semaglutide and other compounding concerns.
Saxenda is approved for: Adults Adults with obesity (BMI of 30 kg/m or greater) Adults who are overweight (BMI of 27 kg/m or greater) and have at least one weight-related health condition, such as high blood pressure, type 2 diabetes, or high cholesterol Children aged 12 and older Adolescents with obesity who weigh more than 60 kg (132 pounds) Limitations of use Saxenda should not be used together with other medicines that contain liraglutide, such as Victoza, or with any other GLP-1 receptor agonist, such as Ozempic, Wegovy, or Trulicity The safety and effectiveness of Saxenda in children aged 12 to 17 years who have type 2 diabetes have not been established
Important contraception consideration: Tirzepatide delays gastric emptying and can reduce the absorption of oral contraceptives
